Three New Biologic Products for Spine Surgery

NuVasive, Inc. has announced U.S. commercial launch of three new biologics offerings: a traditional bone allograft, an amniotic membrane DS implant and additional form factors for the current Propel DBM [demineralized bone matrix] product line.

Here are the details for each new biologic product:

• Traditional Bone Allograft line will offer surgeons “… cancellous chips, demineralized cancellous chips, cortical cancellous chips and cancellous crushed, which all function as economical bone graft options. Traditional Bone Allograft has osteoconductive properties that provide a scaffold for bone growth, and can be packed into bony voids or gaps in a patient’s skeletal system. This product is available in a variety of grind sizes and volumes.”
• Amniotic Membrane DS “… is a double-sided layer of human amniotic membrane which is intended to be a biologic barrier that may help prevent adhesions and reduce scar tissue formation near adjacent muscle, nerve and fascia layer tissue. The strong, pliable properties of this biologic help it adapt to the surrounding anatomy making it easy to handle and position into place. Amniotic Membrane DS is naturally rich in growth factors and has been shown to control inflammation and reduce bacterial and viral activity at the surgical site, supporting the patient’s overall healing process.”
• Propel DBM “… product line, launched in 2017, now introduces gel, gel plus and putty plus as additional form factors with enhanced handling properties to address surgeon preferences. The gel form factor is packaged in a syringe for convenient graft delivery, while Propel DBM putty plus and gel plus contain cancellous chips for additional osteoconductive properties helping promote bone growth. With a variety of DBM form factors available, surgeons can tailor the graft selection to the clinical needs of the patient.”

“The addition of these three new product lines strengthens our comprehensive spine portfolio and further positions NuVasive as a full-service provider of biologics,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “NuVasive is committed to investing in innovative offerings to meet the clinical and economic needs of our patients, surgeons and hospital partners.”

Albert Cornejo, head of NuVasive Biologics, told OTW, “Biologics is an important product line within NuVasive’s spine portfolio, and one that we will continue to evolve. In particular, over the last year, NuVasive now offers everything from stem cell, to DBMs, to synthetics and in a variety of form factors like gels, putty and paste. This helps meet nearly all clinical and economical needs for hospitals.”